Literature DB >> 4053273

Platinum concentration in human tumors of head and neck, uterine cervix, and breast following treatment with cisplatin.

B Hecquet, P Vennin, C Fournier, J L Lefebvre, A Caty, J Bonneterre, L Adenis, A Demaille.   

Abstract

Intratumoral platinum concentrations were measured in three tumor sites (head and neck, uterine cervix, and breast) 48 h after cisplatin administration according to the same protocol. The platinum levels were in the same order of magnitude in all tumors, but the concentration in breast tumors was found to be higher than that in tumors of the head and neck and of the uterine cervix.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 4053273     DOI： 10.1007/BF00263908

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  11 in total

1.  Analysis of platinum in biological materials by flameless atomic absorption spectrophotometry.

Authors:  A F LeRoy; M L Wehling; H L Sponseller; W S Friauf; R E Solomon; R L Dedrick; C L Litterst; T E Gram; A M Guarino; D A Becker
Journal:  Biochem Med       Date:  1977-10

2.  Distribution and retention of the antitumor agent 195mPt-cis-dichlorodiammine platinum (II) in man.

Authors:  H S Smith; D M Taylor
Journal:  J Nucl Med       Date:  1974-05       Impact factor: 10.057

3.  The antitumor agent cis-Pt(NH 3 ) 2 Cl 2 : distribution studies and dose calculations for 193m Pt and 195m Pt.

Authors:  R C Lange; R P Spencer; H C Harder
Journal:  J Nucl Med       Date:  1973-04       Impact factor: 10.057

4.  Human central nervous system distribution of cis-diamminedichloroplatinum and use as a radiosensitizer in malignant brain tumors.

Authors:  D J Stewart; M Leavens; M Maor; L Feun; M Luna; J Bonura; R Caprioli; T L Loo; R S Benjamin
Journal:  Cancer Res       Date:  1982-06       Impact factor: 12.701

5.  In vitro interactions of TNO6 with human plasma.

Authors:  B Hecquet; L Adenis; A Demaille
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

6.  Disposition and distribution of platinum following parenteral administration of cis-dichlorodiammineplatinum(II) to animals.

Authors:  C L Litterst; A F LeRoy; A M Guarino
Journal:  Cancer Treat Rep       Date:  1979 Sep-Oct

7.  Pre-cystectomy intra-arterial cis-diamminedichloroplatinum II with local bladder hyperthermia for bladder cancer.

Authors:  S C Jacobs; S L McCellan; C Maher; R K Lawson
Journal:  J Urol       Date:  1984-03       Impact factor: 7.450

8.  Platinum concentrations in human glioblastoma multiforme following the use of cisplatin.

Authors:  E M Bonnem; C L Litterst; F P Smith
Journal:  Cancer Treat Rep       Date:  1982-08

9.  A comparative study of the distribution in the male rat of platinum-labelled cis-dichlorodiammine platinum (II), cis-trans-dichlorodihydroxy-bis-(isopropylamine) platinum (I), and cis-dichloro-bis-cyclopropylamine platinum (II).

Authors:  R Harrison; C A McAuliffe; A Zaki; J Baer; H Sharma; A Smith; H Jackson; B W Fox
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

10.  Human tissue distribution of platinum after cis-diamminedichloroplatinum.

Authors:  D J Stewart; R S Benjamin; M Luna; L Feun; R Caprioli; W Seifert; T L Loo
Journal:  Cancer Chemother Pharmacol       Date:  1982-12       Impact factor: 3.333
View more
  3 in total

1.  Tumor-tissue and plasma concentrations of platinum during chemotherapy of non-small-cell lung cancer patients.

Authors:  J L Pujol; D Cupissol; C Gestin-Boyer; J Bres; B Serrou; F B Michel
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  Disposition and tumour concentrations of platinum in hypoalbuminaemic patients after treatment with cisplatin for cancer of the head and neck.

Authors:  J D Holding; W E Lindup; D A Bowdler; M Z Siodlak; P M Stell
Journal:  Br J Clin Pharmacol       Date:  1991-08       Impact factor: 4.335

3.  Laser-assisted delivery enhances topical uptake of the anticancer agent cisplatin.

Authors:  Emily Wenande; Uffe H Olesen; Malene R Boesen; Daniel P Persson; Catharina M Lerche; Stefan Stürup; Bente Gammelgaard; Søren Husted; R Rox Anderson; Merete Haedersdal
Journal:  Drug Deliv       Date:  2018-11       Impact factor: 6.419
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.